Answers are grounded in this paper and cite their sources.
Purpose: Low-dose-rate (LDR) brachytherapy has been established as an effective and safe treatment option for men with low and intermediate risk prostate cancer.In this retrospective analysis, we sought to study the effect of body mass index (BMI) on post-implant dosimetric quality.Material and methods: After institutional approval, records of patients with non-metastatic prostate cancer treated in Puerto Rico with LDR brachytherapy during 2008-2013 were reviewed.All patients were implanted with 125 I seeds to a prescription dose of 145 Gy.Computed tomography (CT) based dosimetry was performed 1 month after implant.Patients with at least 1 year of prostate-specific antigen (PSA) follow-up were included.Factors predictive of adequate D 90 coverage (≥ 140 Gy) were compared via the Pearson χ 2 or Wilcoxon rank-sum test as appropriate.Results: One-hundred and four patients were included in this study, with 53 (51%) patients having a D 90 ≥ 140 Gy.The only factor associated with a dosimetric coverage detriment (D 90 < 140 Gy) was BMI ≥ 25 kg/m 2 (p = 0.03).Prostate volume (p = 0.26), initial PSA (p = 0.236), age (p = 0.49), hormone use (p = 0.93), percent of cores positive (p = 0.95), risk group (p = 0.24), tumor stage (p = 0.66), and Gleason score (p = 0.61) did not predict D 90 . Conclusions:In this study we show that BMI is a significant pre-implant predictor of D 90 (< 140 Gy vs. ≥ 140 Gy).Although other studies have reported that prostate volume also affects D 90 , our study did not find this correlation to be statistically significant, likely because all of our patients had a prostate volume < 50 cc.Our study suggests that in patients with higher BMI values, more rigorous peri-implant dosimetric parameters may need to be applied in order to achieve a target D 90 > 140 Gy.
No takes yet. Share an insight, caveat, or question.
Echevarria et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: